Healthy_back (healthy_back) wrote,
Healthy_back
healthy_back

Список литературы к роли Предсердного Натрийуретического Пептида при СХУ и UARS

Содержание https://healthy-back.livejournal.com/420640.html


1. Guilleminault C and De Los Reyes V [2011] Upper‐airway resistance syndrome. Handbook of Clinical Neurology 98: 401‐409.

2. Newman JP, Clerk AA, Moore M, Utley DS and Terris DJ [1996] Recognition and surgical management of the upper airway resistance syndrome. Laryngoscope 106 (9 Pt 1): 1089‐1093.

3. Lin CH and Guilleminault C [2011] Current hypopnea scoring criteria underscore pediatric sleep disordered breathing. Sleep Medicine 12: 720‐729.

4. Ruehland WR, Rochford PD, O’Donoghue FJ, Pierce RJ, Singh P and Thornton AT [2009] The new AASM criteria for scoring hypopneas: impact on the apnea hypopnea index. Sleep 32: 150‐157.

5. Gold AR, Dipalo F, Gold MS and O’Hearn D [2003] The symptoms and signs of upper airway resistance syndrome: a link to the functional somatic syndromes. Chest 123: 87‐95.

6. Guilleminault C, Kirisoglu C, Poyares D, Palombini L, Leger D, Farid‐Moayer M and Ohayon MM [2006] Upper Airway Resistance Syndrome: a long‐term outcome study. J Psychiatr Res 40: 273‐279.

7. Park SY [2008] Sleep Interrupted. New York: Jodev Press, LLC.

8. Haba‐Rubio J, Andries D, Bastardot F, Tobback N, Vollenweider P, Tafti M and Heinzer R [2011] Prevalence of sleep disordered breathing in middle‐aged general population: the Hypnolaus study. Sleep 34: A123

9. Tufik S, Santos‐Silva R, Taddei JA and Azeredo Bittencourt LR [2010] Obstructive sleep apnea syndrome in the Sao Paolo epidemiologic sleep study. Sleep Medicine 11: 441‐446.

10. Umlauf MG and Chasens ER [2003] Sleep disordered breathing and nocturnal polyuria: nocturia and enuresis. Sleep Med Rev 7: 403‐411.

11. Kalra PR and Tigas S [2002] Regulation of lipolysis: natriuretic peptides and the development of cachexia. Int J Cardiol 85: 125‐132.

12. Potter LF, Yoder AR, Flora DR, Antos LK and Dickey DM [2009] Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 191: 341‐366.

13. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA and Livesey JH [1986] Metabolic clearance rate and plasma half life of alpha‐human atrial natriuretic peptide in man. Life Sci 38: 1827‐1833.

14. Kimura K, Yamaguchi Y, Horii M, Kawata H, Yamamoto H, Uemura S and Saito Y [2007] ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol 63: 699‐702.

15. Ikeda N, Yasu T, Nishikimi T, Nakamura T, Kubo N, Kawakami M, Momomura S and Saito M [2007] N‐terminal pro‐atrial natriuretic peptide and exercise prescription in patients with myocardial infarction. Regul Pept 141(1‐3): 154‐158.

16. McKie PM, Cataliotti A, Boerrigter G, Chen HH, Sangaralingham SJ, Martin FL, Ichiki T and Burnett JC Jr [2010] A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension. Hypertension 56: 1152‐1159.

17. Imaizumi T and Takeshita A [1993] Influence of ANP on sympathetic nerve activity and chronotropic regulation of the heart. J Cardiovasc Electrophysiol 4: 719‐729.

18. Porzionato A, Macchi V, Rucinski M, Malendowicz LK and De Caro R [2010] Natriuretic peptides in the regulation of the hypothalamic‐pituitary‐adrenal axis. Int Rev Cell Mol Biol 280: 1‐39.

19. Chartier L, Schiffrin E and Thibault G [1984] Effect of atrial natriuretic factor (ANF)‐related peptides on aldosterone secretion by adrenal glomerulosa cells: critical role of the intramolecular disulphide bond. Biochem Biophys Res Commun 122: 171‐174.

20. Atlas SA, Volpe M, Sosa RE, Laragh JH, Camargo MJ and Maack T [1986] Effects of atrial natriuretic factor on blood pressure and the renin‐angiotensin‐aldosterone system. Fed Proc 45: 2115‐2121.

21. Pizzorno JE and Murray MT [1999] Textbook of Natural Medicine, second edition. Edinburgh: Harcourt Publishers Limited.

22. Demitrack MA, Dale JK and Straus SE [1991] Evidence for impaired activation of the hypothalamic‐pituitary‐adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 73: 1224‐1234.

23. Demiralay C, Jahn H, Kellner M, Yassouridis A and Weidemann K [2010] Influence of exogenous atrial natriuretic peptide on the nocturnal hypothalamic‐pituitary‐adrenal axis and sleep in healthy men. Psychoneuroendocrinology 35: 1438‐1445.

24. Perras B, Schultes B, Behn B, Dodt C, Born J and Fehm HL [2004] Intranasal atrial natriuretic peptide acts as central nervous inhibitor of the hypothalamic‐pituitary‐adrenal stress system in humans. J Clin Endocrinol Metab 89: 4642‐4648.

25. Boneva RS, Decker MJ, Maloney EM, Lin JM, Jones JF, Helgason HG, Heim CM, Rye DB and Reeves WC [2007] Higher heart rate and reduced heart rate variability persist during sleep in chronic fatigue syndrome: a population based study. Auton Neurosci 137: 94‐101.

26. Anderberg UM and Uvnas‐Moberg K [2000] Plasma oxytocin levels in female fibromyalgia syndrome patients. Z Rheumatol 59: 373‐379.

27. Wyller VB, Evang JA, Godang K, Solhjell KK and Bollerslev J [2010] Hormonal alterations in adolescent chronic fatigue syndrome. Acta Paediatr 99: 770‐773.

28. Krakow B, Melendrez D, Warner TD, Dorin R, Harper R and Hollifield M [2002] To breathe, perchance to sleep: sleep‐disordered breathing and chronic insomnia among trauma survivors. Sleep Breath 6: 189‐202.

29. Gold AR [2011] Functional somatic syndromes, anxiety disorders and the upper airway: A matter of paradigms. Sleep Med Rev 15: 389‐401.

30. Amin MM, Belisova Z, Hossain S, Gold MS, Broderick JE and Gold AR [2011] Inspiratory airflow dynamics during sleep in veterans with Gulf War illness: a controlled study. Sleep Breath 15: 333‐339.

31. Freund BJ, Wade CE and Claybaugh J [1988] Effects of exercise on atrial natriuretic factor. Release mechanisms and implications for fluid homeostasis. Sports Med 6: 364‐377.

32. Kita H, Ohi M, Chin K, Noguchi T, Otsuka N, Tsuboi T, Itoh H, Nakao K and Kuno K [1998] The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. J Sleep Res 7: 199‐207.

33. Schafer H, Ehlenz K, Ewig S, Hasper E, Koehler U, Latzelsberger J, Tasci S and Luderitz B [1999] Atrial natriuretic peptide levels and pulmonary artery pressure awake, at exercise and asleep in obstructive sleep apnoea syndrome. J Sleep Res 8: 205‐210.

34. Svatikova A, Shamsuzzaman, AS, Wolk R, Phillips BG, Olson LJ and Somers VK [2004] Plasma brain natriuretic peptide in obstructive sleep apnea. Am J Cardiol 94: 529‐532.

35. Lin CC, Tsan KW and Lin CY [1993] Plasma levels of atrial natriuretic factor in moderate to severe obstructive sleep apnea syndrome. Sleep 16: 37‐39.

36. Ichioka M, Hirata Y, Inase N, Tojo N, Yoshizawa M, Chida M, Miyazato I, Taniai S and Marumo F [1992] Changes of circulating atrial natriuretic peptide and antidiuretic hormone in obstructive sleep apnea syndrome. Respiration 59: 164‐168.

37. Patwardhan AA, Larson MG, Levy D, Benjamin EF, Leip EP, Keyes MJ, Wang TJ, Gottlieb DJ and Vasan RS [2006] Obstructive sleep apnea and plasma natriuretic peptide levels in a community‐based sample. Sleep 29: 1301‐1306.

38. Foster GE, Hanly PJ, Ahmed SB, Beaudin AE, Pialoux V and Poulin MJ [2010] Intermittent hypoxia increases arterial blood pressure in humans through a Renin‐Angiotensin system‐dependent mechanism. Hypertension 56: 369‐377.

39. Møller DS, Lind P, Strunge B and Pedersen EB [2003] Abnormal vasoactive hormones and 24‐hour blood pressure in obstructive sleep apnea. Am J Hypertens 16: 274‐280.

40. Matsukawa T and Miyamoto T [2011] Angiotensin II‐stimulated secretion of arginine vasopressin is inhibited by atrial natriuretic peptide in humans. Am J Physiol Regul Integr Comp Physiol 300: R624‐R629.

41. Oh YB, Gao S, Shah A, Kim JH, Park WH and Kim SH [2011] Endogenous angiotensin II suppresses stretch‐induced ANP secretion via AT1 receptor pathway. Peptides 32: 374‐381.

42. Dietz JR [2005] Mechanisms of atrial natriuretic peptide secretion from the atrium. Cardiovasc Res 66: 8‐17.

43. De Pergola G, Garruti G, Giorgino F, Cospite MR, Corso M, Cignarelli M and Giorgino R [1994] Reduced effectiveness of atrial natriuretic factor in pre‐menopausal obese women. Int J Obes Relat Metab Disord 18: 93‐97.

44. Beltowski J, Jamroz‐Wisniewka A, Borkowska E and Marciniak A [2006] Phosphodiesterase 5 inhibitor ameliorates renal resistance to atrial natriuretic peptide associated with obesity and hyperleptinemia 37: 307‐315.

45. Schiffrin EL and St‐Louis J [1987] Decreased density of vascular receptors for atrial natriuretic peptide in DOCA‐salt hypertensive rats. Hypertension 9: 504‐512.

46. Licata G, Volpe M, Scaglione R and Rubattu S [1994] Salt‐regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 23(1 Suppl): 120‐124.

47. Rubattu, S, Sciarretta S, Ciavarella GM, Venturelli V, De Paolis P, Tocci G, De Biase L, Ferrucci A and Volpe M [2007] Reduced levels of N‐terminal‐proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. J Hypertens 25: 833‐839.

48. Martel G, Hamet P and Tremblay J [2010] Central role of guanylyl cyclase in natriuretic peptide signaling in hypertension and metabolic syndrome. Mol Cell Biochem 334: 53‐65.

49. Nakatsuji H, Maeda N, Hibuse T, Hiuge A, Hirata A, Kuroda Y, Kishida K, Kihara S, Funahashi T and Shimomura I [2010] Reciprocal regulation of natriuretic peptide receptors by insulin in adipose cells. Biochem Biophys Res Commun 392: 100‐105.

50. Moro C, Klimcakova E, Lolmede K, Berlan M, Lafontan M, Stich V, Bouloumie A, Galitzky J, Arner P and Langin D [2007] Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 50: 1038‐1047.

51. Standeven KF, Hess K, Carter AM, Rice GI, Cordell PA, Balmforth AJ, Lu B, Scott DJ, Turner AJ, Hooper NM and Grant PJ [2011] Neprilysin, obesity and the metabolic syndrome. Int J Obes 35: 1031‐1040.

52. http://www.ncbi.nlm.nih.gov/books/NBK22251/ [1998] Obesity. Bethesda, MD: National Center for Biotechnology Information. Accessed January 19, 2011.

53. Yuan K, Yu J, Shah A, Gao S, Kim SY, Kim SZ, Park BH and Kim SH [2010] Leptin reduces plasma ANP level via nitric oxide‐dependent mechanism. Am J Physiol Regul Integr Comp Physiol 298: R1007‐R1016.

54. Beleigoli AM, Diniz MF and Ribiero AL [2009] Natriuretic peptides: linking heart and adipose tissue in obesity and related conditions — A systematic review. Obes Rev 10: 617‐626.

55. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, Yamahara K, Taura D, Inuzuka M, Sonoyama T and Nakao K [2009] Natriuretic peptides/cGMP/cGMP‐dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes 58: 2880‐2892.

56. Sengenes C, Stich V, Berlan M, Hejnova J, Lafontan M, Pariskova Z and Galitzky J [2002] Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low‐calorie diet in obese women. Int J Obes Relat Metab Disord 26: 24‐32.

57. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C and Galitzky J [2008] Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 19: 130‐137.

58. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, Berlan M, Luft FC, Lafontan M, and Jordan J [2005] Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 90: 3622‐3628.

59. Fischer JE and Bland KI [2007] Master of Surgery, volume 1. Fifth edition. Philadelphia: Lippincott Williams & Wilkins, p. 116.

60. Mtinangi BL and Hainsworth R [1998] Early effects of oral salt on plasma volume, orthostatic tolerance, and baroreceptor sensitivity in patients with syncope. Clin Auton Res 8: 231‐235.

61. Tatsumi K, Kasahara Y, Kurosu K, Tanabe N, Takiguchi Y and Kuriyama T [2005] Sleep oxygen desaturation and circulating leptin in obstructive sleep apnea‐hypopnea syndrome. Chest 127: 716‐721.

62. Polotsky VY, Li J, Punjabi NM, Rubin AE, Smith PL, Schwartz AR and OʹDonnell CP [2003] Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 552(Part 1): 253‐264.

63. Qin L, Xiang Y, Song Z, Jing R, Hu C and Howard ST [2010] Erythropoetin as a possible mechanism for the effects of intermittent hypoxia on bodyweight, serum glucose and leptin in mice. Regul Pept 165: 168‐173.

64. Schulz R, Flötotto C, Jahn A, Eisele HJ, Weissmann N, Seeger W and Rose F [2006] Circulating adrenomedullin in obstructive sleep apnoea. J Sleep Res 15: 89‐95.

65. Chen YF [2005] Atrial natriuretic peptide in hypoxia. Peptides 26(6):1068‐77.

66. Kraiczi H, Magga J, Sun XY, Ruskoaho H, Zhao X and Hedner J [1999] Hypoxic pressor response, cardiac size, and natriuretic peptides are modified by long‐term intermittent hypoxia. J Appl Physiol 87: 2025‐2031.

67. Jiao J and Baertschi A [1993] Neural control of the endocrine rat heart. Proc Natl Acad Sci USA 90: 7799‐7803.

68. Sariman N, Levent E, Aksungar FB, Soylu AC and Bektas O [2010] Homocysteine levels and echocardiographic findings in obstructive sleep apnea syndrome. Respiration 79: 38‐45.

69. Gaillard CA, Koomans, HA and Mees EJ [1988] Enalapril attenuates natriuresis of atrial natriuretic factor in humans. Hypertension 11: 160‐165.

70. Ha YS, Tchey DU, Kang HW, Kim YJ, Yun SJ, Lee SC and Kim WJ [2010] Phosphaturia as a promising predictor of recurrent stone formation in patients with urolithiasis. Korean J Urol 51: 54‐59.

71. Sahebjani H [1998] Changes in urinary uric acid excretion in obstructive sleep apnea before and after therapy with nasal continuous positive airway pressure. Chest 113: 1604‐1608.

72. Saito H, Nishimura M, Shibuya E, Makita H, Tsujino I, Miyamoto K and Kawakami Y [2002] Tissue hypoxia in sleep apnea syndrome assessed by uric acid and adenosine. Chest 122: 1686‐1694.

73. Nadler JL and Rude RK [1995] Disorders of magnesium metabolism. Endocrinol Metab Clin North Am 24: 623‐641.

74. Pall ML [2007] Explaining “Unexplained Illnesses” New York: The Haworth Press, Inc.

75. Nielsen FH [2010] Magnesium, inflammation, and obesity in chronic disease. Nutr Rev 68(6):333‐40.

76. Fox CH, Ramsoomair D, Mahoney MC, Carter C, Young B and Graham R [1999] An investigation of hypomagnesemia among ambulatory urban African Americans. J Fam Pract 48: 636‐639.

77. Fox CH, Mahoney MC, Ramsoomair D and Carter CA [2003] Magnesium deficiency in African‐Americans: Does it contribute to increased cardiovascular risk factors? J Nat Med Assoc 95: 257‐262.

78. Rayssiguier Y, Libako P, Nowacki W and Rock E [2010] Magnesium deficiency and metabolic syndrome: stress and inflammation may reflect calcium activation. Magnes Res 23: 73‐80.

79. Douban S, Brodsky MA, Whang DD and Whang R [1996] Significance of magnesium in congestive heart failure. Am Heart Journal 132: 664‐671.

80. Jones MD [2009] Deadly Sleep. New York: iUniverse Books.

81. McKie PM, Catalotti A, Huntley BK, Martin FL, Olson TM and Burnett JC Jr [2009] A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure‐lowering, renal‐enhancing, and aldosterone‐suppressing actions. J Am Coll Cardiol 54: 1024‐1032.

82. Resnick, LM, Barbagallo M, Bardicef M, Bardicef O, Sorokin Y, Evelhoch J, Dominguez LJ, Mason BA and Cotton DB [2004] Cellular‐free magnesium depletion in brain and muscle of normal and preeclamptic pregnancy: a nuclear magnetic resonance spectroscopic study. Hypertension 44: 322‐326.

83. Champagne KA, Kimoff RJ, Barriga PC and Schwartzman K [2010] Sleep disordered breathing in women of childbearing age & during pregnancy. Indian J Med Res 131: 285‐301.

84. Guilleminault C, Palombini L, Poyares D, Takaoka S, Huynh NT and El‐Sayed Y [2007] Pre‐eclampsia and nasal CPAP: part 1. Early intervention with nasal CPAP in pregnant women with risk factors for pre‐eclampsia: preliminary findings. Sleep Med 9: 9‐14.

85. Poyares D, Guilleminault C, Hachul H, Fujita L, Takaoka S, Tufik S and Sass N [2007] Pre‐eclampsia and nasal CPAP: Part 2. Hypertension during pregnancy, chronic snoring, and early nasal CPAP intervention. Sleep Med 9: 15‐21.

86. Spaanderman M, Ekhart, van Eyck J, de Leeuw P and Peeters L [2001] Preeclampsia and maladaptation to pregnancy: a role for atrial natriuretic peptide? Kidney Int 60: 1397‐1406.

87. Welch KMA [2003] Contemporary concepts of migraine pathogenesis. Neurology 61(8 Suppl. 4): S2‐S8.

88. Demirkaya S, Vural O, Dora B and Topcuoglu MA [2001] Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. Headache 41: 171‐177.

89. Peikert A, Wilimzig C and Kohne‐Volland R [1996] Prophylaxis of migraine with oral magnesium: results from a prospective, multicenter, placebo‐controlled and double‐blind randomized study. Cephalalgia 16: 257‐263.

90. Swaminathan R [2003] Magnesium metabolism and its disorders. Clin Biochem Rev 24: 47‐66.

91. González Bosc LV, Majowicz MP and Vidal NA [2000] Effects of atrial natriuretic peptide in the gut. Peptides 21: 875‐887.

92. Vesely DL, San Miguel GI, Hassan I, Gower WR Jr and Schocken DD [2001] Atrial natriuretic hormone, vessel dilator, long‐acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of total and free T4 and free T3 with reciprocal increase in TSH. J Clin Endocrinol Metab 86: 5438‐5442.

93. Everson CA and Reed HL [1995] Pituitary and peripheral thyroid hormone responses to thyrotropin‐releasing hormone during sustained sleep deprivation in freely moving rats. Endocrinology 136: 1426‐1434.

94. Everson C and Nowak TS Jr [2002] Hypothalamic thyrotropin‐releasing hormone mRNA responses to hypothyroxinemia induced by sleep deprivation. Am J Physiol Endocrinol Metab 283: E85‐E93.

95. Erden S, Cagatay T, Buyukozturk S, Kiyan E and Cuhadaroglu C [2004] Hashimoto thyroiditis and obstructive sleep apnea syndrome: is there any relation between them? Eur J Med Res 9: 570‐572.

96. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR and Burnett JC Jr [2002] Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40: 976‐982.

97. Clerico A, Del Ry S, Maffei S, Prontera C, Emdin M and Giannessi D [2002] The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clin Chem Lab Med 40: 371‐377.

98. Chang AY, Abdullah SM, Jain T, Stanek HG, Das SR, McGuire DK, Auchus RJ and de Lemos JA [2007] Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol 49: 109‐116.

99. Battista MC, Oligny LL, St‐Louis J and Brochu M [2002] Intrauterine growth restriction in rats is associated with hypertension and renal dysfunction in adulthood. Am J Physiol Endocrinol Metab 283: E124‐E131.

100. Bridgeman P, Aronovitz MA, Kakkar R, Oliverio MI, Coffman TM, Rand WM, Konstam MA, Mendelsohn ME and Patten RD [2005] Gender‐specific patterns of left ventricular and myocyte remodeling following myocardial infarction in mice deficient in the angiotensin II type 1a receptor. Am J Physiol Heart Circ Physiol 289: H586‐H592.

101. Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, Janssen B, van Eys G, Grohé C and Doevendans PA [2006] Estrogen receptor beta protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol 26: 1524‐1530.

102. Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJ, Grohé C, van Bilsen M and Doevendans PA [2004] 17β‐Estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor‐cyclic guanosine monophosphate‐dependent protein kinase pathway. Circulation 109: 269‐276.

103. Deng Y and Kaufman S [1993] The influence of reproductive hormones on ANF release by rat atria. Life Sci 53: 689‐696.

104. Panayiotou CM, Baliga R, Stidwell R, Taylor V, Singer M and Hobbs AJ [2010] Resistance to endotoxic shock in mice lacking natriuretic peptide receptor‐A. Br J Pharmacol 160: 2045‐2054.

105. http://cgmp.blauplanet.com/path.html [2007] Dr. Luis Agullo December 28, 2007 Cyclic GMP Site, accessed June 13, 2011

106. Piggott LA, Hassell KA, Berkova Z, Morris AP, Silberbach M and Rich TC [2006] Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments. J Gen Physiol 128: 3‐14.

107. Kotlo KU, Rasenick MM and Danziger RS [2010] Evidence for cross‐talk between atrial natriuretic peptide and nitric oxide receptors. Mol Cell Biochem 338: 183‐189.

108. William M, Hamilton EJ, Garcia A, Bundgaard H, Chia KK, Figtree GA and Rasmussen HH [2008] Natriuretic peptides stimulate the cardiac sodium pump via NPR‐C‐coupled NOS activation. Am J Physiol Cell Physiol 294: C1067‐C1073.

109. Elesgaray R, Caniffi C, Ierace DR, Jaime MF, Fellet A, Arranz C and Costa MA [2008] Signaling cascade that mediates endothelial nitric oxide synthase activation induced by atrial natriuretic peptide. Regul Pept 151: 130‐134.

110. Costa MA, Elesgaray R, Caniffi C, Fellet A, MacLaughlin M and Arranz C [2010] Role of nitric oxide as a key mediator on cardiovascular actions of atrial natriuretic peptide in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 298: H778‐H786

111. Nakayama R, Harada N, Asano M, Nomura N, Saito T, Mishima A and Okajima K [2007] Atrial natriuretic peptide reduces ischemia/reperfusion‐induced spinal cord injury in rats by enhancing sensory neuron activation. J Pharmacol Exp Ther 322: 582‐590.

112. Eftekhari S and Edvinsson L [2010] Possible sites of action of the new calcitonin gene‐related peptide receptor antagonists. Ther Adv Neurol Disord 3: 369‐378.

113. Wiggins AK, Shen PJ and Gundlach AL [2003] Atrial natriuretic peptide expression is increased in rat cerebral cortex following spreading depression: possible contribution to sd‐induced neuroprotection. Neuroscience 118: 715‐726.

114. Palazzo E, Luongo L, de Novellis V, Berrino L, Rossi F and Maione S [2010] Moving towards supraspinal TRPV1 receptors for chronic pain relief. Mol Pain 6: 66.

115. Church DJ, Arkinstall SJ, Vallotton MB, Chollet A, Kawashima E and Lang U [1996] Stimulation of atrial natriuretic peptide release by neurokinins in neonatal rat ventricular cardiomyocytes. Am J Physiol 270(3 Part 2): H935‐H944.

116. Piao FL, Cao C, Han JH, Kim SZ and Kim SH [2004] Calcitonin gene‐related peptide‐induced suppression of atrial natriuretic peptide release through receptors for CGRP1 but not for calcitonin and amylin. Eur J Pharmacol 483: 295‐300.

117. Schiebinger RJ and Santora AC [1989] Stimulation by calcitonin gene‐related peptide of atrial natriuretic peptide secretion in vitro and its mechanism of action. Endocrinology 124: 2473‐2479.

118. Yamamoto A, Kimura S, Hasui K, Fujisawa Y, Tamaki T, Fukui K, Iwao H and Abe Y [1988] Calcitonin gene‐related peptide (CGRP) stimulates the release of atrial natriuretic peptide (ANP) from isolated rat atria. Biochem Biophys Res Commun 155: 1452‐1458.

119. Cortright DN and Szallasi A [2004] Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem 271: 1814‐1819.

120. Lin Q, Li D, Xu X, Zou X and Fang L [2007] Roles of TRPV1 and neuropeptidergic receptors in dorsal root reflex‐mediated neurogenic inflammation induced by intradermal injection of capsaicin. Mol Pain 3: 30.

121. Kuribayashi K, Kitaoka Y, Kumai T, Munemasa Y, Kitaoka Y, Isenoumi K, Motoki M, Kogo J, Hayashi Y, Kobayashi S and Ueno S [2006] Neuroprotective effect of atrial natriuretic peptide against NMDA‐induced neurotoxicity in the rat retina. Brain Res 1071: 34‐41.

122. Kovács GL [2000] Atrial natriuretic peptide modulates N‐methyl‐D‐aspartate‐induced hyperexcitability in ethanol‐dependent mice. Eur J Pharmacol 401: 343‐347.

123. Bjelland I, Tell GS, Vollset SE, Refsum H and Ueland PM [2003] Folate, vitamin B12, homocysteine, and the MTHFR 677C‐>T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry 60: 618‐626.

124. De Vito P, Incerpi S, Pedersen JZ and Luly P [2010] Atrial natriuretic peptide and oxidative stress. Peptides 31: 1412‐1419.

125. Scarpino S, Marchitti S, Stanzione R, Evangelista A, Di Castro S, Savoia C, Quarta G, Sciarretta S, Ruco L, Volpe M, and Rubattu S [2009] Reactive oxygen species‐mediated effects on vascular remodeling induced by human atrial natriuretic peptide T2238C molecular variant in endothelial cells in vitro. J Hypertens 27: 1804‐1813.

126. Nannipieri M, Manganiello M, Pezzatini A, De Bellis A, Seghieri G and Ferrannini E [2001] Polymorphisms in the hANP (human atrial natriuretic peptide) gene, albuminuria, and hypertension. Hypertension 37: 1416‐1422.

127. Koga H, Hagiwara S, Shingu C, Matsumoto S, Yokoi I and Noguchi T [2010] Human atrial natriuretic peptide ameliorates LPS‐induced acute lung injury in rats. Lung 188: 241‐246.

128. Vellaichamy E, Kaur K and Pandey KN [2007] Enhanced activation of pro‐inflammatory cytokines in mice lacking natriuretic peptide receptor‐A. Peptides 28: 893‐899.

129. Ladetzki‐Baehs K, Keller M, Kiemer AK, Koch E, Zahler S, Wendel A and Vollmar AM [2007] Atrial natriuretic peptide, a regulator of nuclear factor‐kappaB activation in vivo. Endocrinology 148: 332‐336.

130. Kiemer AK, Weber NC and Vollmar AM [2002] Induction of IkappaB: atrial natriuretic peptide as a regulator of the NF‐kappaB pathway. Biochem Biophys Res Commun 295: 1068‐1076.

131. Baldwin CM, Kapur VK, Holberg CJ, Rosen C, Nieto FJ and Sleep Heart Health Study Group [2004] Associations between gender and measures of daytime somnolence in the Sleep Heart Health Study. Sleep 27: 305‐311.

132. Krakow B [2007] Sound Sleep, Sound Mind. Hoboken, NJ: John Wiley and Sons, Inc.

133. Yuan K, Kim SY, Oh YB, Yu J, Shah A, Park BH and Kim SH [2010] Upregulation of ANP and NPR‐C mRNA in the kidney and heart of eNOS knockout mice. Peptides 31: 1319‐1325.

134. Dickey DM, Yoder AR and Potter LR [2009] A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation. J Biol Chem 284(29):19196‐202.

135. Yasko A [2005] Genetic ByPass. Matrix Development Publishing.

136. Blaise S, Alberto JM, Nédélec E, Ayav A, Pourié G, Bronowicki JP, Guéant JL and Daval JL [2005] Mild neonatal hypoxia exacerbates the effects of vitamin‐deficient diet on homocysteine metabolism in rats. Pediatr Res 57: 777‐782.

137. Levine J, Timinsky I, Vishne T, Dwolatzky T, Roitman S, Kaplan Z, Kotler M, Sela BA and Spivak B [2008] Elevated serum homocysteine levels in male patients with PTSD. Depress Anxiety 25: E154‐E157.

138. Wang L, Li J, Xie Y and Zhang XG [2010] Association between serum homocysteine and oxidative stress in elderly patients with obstructive sleep apnea/hypopnea syndrome. Biomed Environ Sci 23: 42‐47.

139. Jendricko T, Vidović A, Grubisić‐Ilić M, Romić Z, Kovacić Z and Kozarić‐Kovacić D [2009] Homocysteine and seum lipids concentration in male war veterans with posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 33: 134‐140.

140. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, DʹAgostino RB, Wilson PW and Wolf PA [2002] Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 346(7):476‐83.

141. Scholl TO and Johnson WG [2000] Folic acid: influence on the outcome of pregnancy. Am J Clin Nutr 71(5 Suppl): 1295S‐1303S.

142. James SJ, Melnyk S, Jernigan S, Pavliv O, Trusty T, Lehman S, Seidel L, Gaylor DW and Cleves MA [2010] A functional polymorphism in the reduced folate carrier gene and DNA hypomethylation in mothers of children with autism. Am J Med Genet B Neuropsychiatr Genet 153B: 1209‐1220.

143. Mann JR, McDermott S, Bao H, Hardin J and Gregg A [2010] Pre‐eclampsia, birth weight, and autism spectrum disorders. J Autism Dev Disord 40: 548‐554.

144. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW and Neubrander JA [2004] Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80: 1611‐1617.

145. Adams M, Lucock M, Stuart J, Fardell S, Baker K and Ng X [2007] Preliminary evidence for involvement of the folate gene polymorphism 19bp deletion‐DHFR in occurence of autism. Neurosci Lett 422: 24‐29.

146. Bidzseranova A, Gueron J, Penk B and Telegdy G [1991] The effects of atrial natriuretic peptide on active avoidance behavior in rats. The role of neurotransmitters. Pharmacol Biochem Behav 40: 61‐64.

147. Chila A, Fitzgerald M [2011] Foundations of Osteopathic Medicine, American Osteopathic Association. Philadelphia: Lippincott, Williams and Wilkins.

148. Liu PY, Yee B, Wishart SM, Jimenez M, Jung DG, Grunstein RR and Handelsman DJ [2003] The short‐term effects of high‐dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 88: 3605‐3613.

149. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A and White DP [2001] Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 86: 1175‐1180.

Conflict of interest statement: The author has no conflict of interest to declare.
Subscribe

  • Post a new comment

    Error

    default userpic

    Your reply will be screened

    Your IP address will be recorded 

    When you submit the form an invisible reCAPTCHA check will be performed.
    You must follow the Privacy Policy and Google Terms of use.
  • 0 comments